Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.

ABSTRACT:

Background

Identifying treatments for triple-negative breast cancer (TNBC) remains a critical medical need. We have found that Interleukin 13 receptor alpha 2 (IL-13RA2), EphA2, EphA3 and EphB2 receptors are over-expressed collectively in majority of patients with breast cancer and its brain metastases. We are pursuing the novel idea of targeting these four tumor-associated receptors identified by us with one pharmaceutical compound. A compound, called QUAD, was designed and constructed, which binds all four targeted receptors.

Methods

We have examined the presence of IL-13RA2, EphA2, EphA3 and EphB2 receptors in breast cancer cells in vitro, tissue micro-arrays including involved lymph nodes, and in paired primary tumor-brain metastases, including two subtypes of breast can

SUBMITTER: Debinski W 

PROVIDER: S-EPMC12560510 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature